Copy number variations associated with abnormal gene dosage have an important role in the genetic etiology of many neurodevelopmental disorders, including intellectual disability (ID) and autism. We hypothesize that the chromosome 2q23.1 region encompassing MBD5 is a dosage-dependent region, wherein deletion or duplication results in altered gene dosage. We previously established the 2q23.1 microdeletion syndrome and report herein 23 individuals with 2q23.1 duplications, thus establishing a complementary duplication syndrome. The observed phenotype includes ID, language impairments, infantile hypotonia and gross motor delay, behavioral problems, autistic features, dysmorphic facial features (pinnae anomalies, arched eyebrows, prominent nose, small chin, thin upper lip), and minor digital anomalies (fifth finger clinodactyly and large broad first toe). The microduplication size varies among all cases and ranges from 68 kb to 53.7 Mb, encompassing a region that includes MBD5, an important factor in methylation patterning and epigenetic regulation. We previously reported that haploinsufficiency of MBD5 is the primary causal factor in 2q23.1 microdeletion syndrome and that mutations in MBD5 are associated with autism. In this study, we demonstrate that MBD5 is the only gene in common among all duplication cases and that overexpression of MBD5 is likely responsible for the core clinical features present in 2q23.1 microduplication syndrome. Phenotypic analyses suggest that 2q23.1 duplication results in a slightly less severe phenotype than the reciprocal deletion. The features associated with a deletion, mutation or duplication of MBD5 and the gene expression changes observed support MBD5 as a dosage-sensitive gene critical for normal development.
INTRODUCTION
Copy number variations (CNVs) have an important role in the genetic etiology of many neurodevelopmental disorders, including intellectual disability (ID) and autism. Studies show that neurodevelopmental syndromes associated with CNVs emerge from abnormal gene dosage, suggesting that strict regulation of gene dosage at some loci is required for proper neurodevelopment. These genes are labeled dosage-sensitive genes, and alteration in the expression of these genes can lead to considerable phenotypic effects. In this study, we continue to delineate another dosage-sensitive gene associated with reciprocal deletion and duplication syndromes. We previously implicated the chromosome 2q23.1 region in genomic disease. 1 We reported that methyl-CpG-binding domain 5 (MBD5) is the major disease gene responsible for 2q23.1 deletion syndrome in 65 patients, with haploinsufficiency of MBD5 resulting from a variety of 2q23.1 deletions. 1 Furthermore, we showed that the phenotypes associated with a deletion or mutation of MBD5 were similar. Duplications of MBD5 have been reported sporadically in the literature. Our group recently reported two patients with 2q23.1 duplications that included MBD5. 2 In a study, in which rare copy number variants in autism spectrum disorders were analyzed, one individual presented with a 2q23.1 duplication that included the MBD5 gene. 3 Before that report, three larger duplications in the 2q23 region were reported. [4] [5] [6] Furthermore, the DECIPHER database has six duplications that involve MBD5 (DECIPHER ID 251237, 251363, 248386, 251953, 254507 and 260771). Here, we report 23 new patients with microduplication of 2q23.1, for a total of 36 cases, establishing a duplication syndrome complementary to the microdeletion syndrome. We further demonstrate that MBD5 is a dosage-sensitive gene and that improper MBD5 dosage affects normal neurodevelopment and is likely a major player in the development of key clinical features present in both the 2q23.1 deletion syndrome and the 2q23.1 duplication syndrome.
MATERIALS AND METHODS Subjects
We established an international collaboration to collect a cohort of individuals with duplications involving chromosome band 2q23.1 from microarray-based comparative genomic hybridization analyses. When available, peripheral blood was collected, and DNA, RNA, and lymphoblastoid cell lines (LCLs, human lymphocytes transformed with Epstein-Barr virus) were prepared according to standard methods. Phenotypic information was obtained from diagnostic referral data, medical records, clinical reports, genetics clinic evaluations, neurodevelopmental and/or psychological evaluations, parent surveys, photos, previously published articles and/or a clinical checklist sent to the referring physician or care provider. All samples and information were collected after informed consent was obtained and in accordance with local institutional review board approved protocols from Virginia Commonwealth University, The Hospital for Sick Children, The Mayo Clinic, Radboud University Nijmegen Medical Center and Nationwide Children's Hospital.
Phenotype analysis
Data were collected for characteristics related to subjects' medical and developmental history and neurological, behavioral and physical features ( Table 1 ). Characteristics that were age dependent (behavior, sleep patterns and craniofacial, and skeletal abnormalities) were scored accordingly on the basis of development. Autistic-like symptoms were defined as having reported autistic-like behaviors, were specifically evaluated with the ADOS or ADI-R or were given a diagnosis of pervasive developmental disorder. Eye and pinnae abnormalities varied among subjects and were grouped in broad categories. A detailed phenotype analysis was performed on data collected from a subset of the 23 patients with 2q23.1 duplication syndrome and compared with the core characteristics associated with 2q23.1 deletion, partial or complete MBD5-specific deletions and MBD5 mutations. 1 Ten subjects had in-depth clinical characterizations, and their features were compared in Table 1 .
Expression analyses
LCLs from 2q23.1 duplication syndrome patients and controls were cultured according to standard methods. RNA was isolated from LCLs or lymphocytes collected from fresh blood, and cDNA was prepared according to published methods. 7 Quantitative RT-PCR for assessment of MBD5 mRNA expression was performed as previously described. 1 Briefly, predesigned Assays on Demand Gene Expression Products (Fermentus, Glen Burnie, MD, USA) Taqman minor groove binder (MGB) probes for MBD5 (Hs02289233_m1) were used (Applied Biosystems, Inc.) with GAPDH (MIM 138400) (Hs99999905_m1) as the endogenous control. All cDNA samples were run in triplicate in 10 ml reaction volumes. Taqman Universal PCR Master Mix (Applied Biosystems, Life Technologies, Inc., Grand Island, NY, USA), the probe, and deionized water were mixed together in a fixed ratio, and cDNA was then added to each well. PCR conditions were the Standard 7500 Run mode of the ABI Prism 7900 HT Sequence Detection System (Applied Biosystems). Cycle threshold (C t ) was determined during the geometric phase of the PCR amplification plots, as recommended by the manufacturer. Relative differences in transcript levels were quantified according to the DDC t method and normalized to GAPDH. Data were analyzed with 7500 Fast System SDS Software (Applied Biosystems). Standard error was generated for each sample as previously described, and significance (Po0.05) was determined by a one-sample t-test compared with theoretical mean of 1.0 (Po0.001 for all deletion and duplication cases). Results are expressed as fold-change relative to 1.0 (normal control). We then compared mRNA expression of MBD5 in 2q23.1 duplication subjects to that of our previously published MBD5 expression studies in 2q23.1 deletion subjects. 1 
Statistical analyses
Statistical analysis for gene expression data was performed with Prism 4 version 4.0b (GraphPad Software), as previously described. 1 
RESULTS
The analyses presented here characterize the molecular genetic and phenotypic heterogeneity associated with the 2q23.1 microduplication syndrome. We provide data to support MBD5 as the critical gene for both 2q23.1 deletion and duplication syndromes and demonstrate that appropriate dosage of MBD5 is critical for normal development.
Refinement of the 2q23.1 duplication syndrome critical region Given the establishment of MBD5 haploinsufficiency and 2q23.1 microdeletion as a significant neurodevelopmental syndrome, we questioned whether duplication of this region also contributed to neurodevelopmental abnormalities. Thus, we searched for duplications of MBD5 across academic and commercial testing databases and identified 36 cases with microduplications of 2q23.1, including 6 cases described in DECIPHER, 6 reported cases, [2] [3] [4] [5] [6] Table 1 ). Aligning the 2q23.1 duplications, the smallest region of overlap (SRO) was defined to one gene, MBD5, common to all duplications (Figure 1) . No other genes were included in the SRO for all duplications or were present in duplications that did not also involve MBD5. Furthermore, the alignment of deletion and duplication regions revealed a common SRO that included only MBD5 (Figure 1 ). Importantly, duplications disrupting any translated or untranslated exons of MBD5 are not present in a control population of 13 991 individuals. 8 All of the 2q23.1 duplications presented in this report are unrelated and are either de novo or of unknown inheritance with the exception of three cases that show transmission from mother to child (3/36 or 8.3% with maternal inheritance). GC19184a and GC19184b represent transmission from a mother to her son. The 8-year-old boy was referred for developmental delay, dysmorphic features and multiple joint contractures. GC3057a and GC3057b represent maternal inheritance from a mother to her 4-year-old daughter, referred for developmental delay and cerebellar ataxia. Cases 3424_3a and 3424_3b represent a reported case of a mother and her son, who presented with autism, mild ID and relative macrocephaly. 3 Detailed clinical information on the mothers in these cases was not available; however, mothers were not considered to be affected by the evaluating clinicians.
Phenotype analyses show overlapping features between individuals with duplication or deletion of 2q23.1 In the literature, the phenotype associated with 2q23.1 duplications included developmental delay, seizures, hypotonia, mild dysmorphic features and behavioral problems with autistic features; however, a complete description of this disorder has not been elucidated. [2] [3] [4] [5] [6] Given the large number of samples with more comprehensive phenotypic description and the common duplication of MBD5 in all cases (Figure 1 ), we were able to provide a more detailed clinical characterization of 2q23.1 microduplication syndrome, comparing 34 features in 10 individuals for whom in-depth clinical information was available. Of the 28 most commonly reported features, all subjects had developmental delay, motor delay, language impairment and infantile hypotonia (Table 1) . Behavioral problems and autistic-like symptoms were observed in all but one of the 23 new duplication cases, and all were noted to have affable personalities (Table 1) . SMS397 was noted to be very affectionate and social and with an overdeveloped and musical ear, similar to that reported in Williams syndrome. SMS376 was described as a likeable teenager with high cognitive function despite her language impairment. While the subjects had craniofacial manifestations, these were generally mild anomalies and not consistent among all individuals (Figure 2) . However, hypotelorism, downslanting palpebral fissures, arched eyebrows, bilateral ptosis, long eyelashes, prominent noses, pinnae abnormalities and wide mouth were noted in most of the subjects evaluated (Table 1, Figure 2 ). Thin upper lip and small chin/micrognathia/retrognathia were also reported (Table 1) . However, SMS381 was reported to have hypertelorism, telecanthus and full lips, indicating that considerable variability in the craniofacial features may be present. Subjects appear to have small noses with thick nasal tip when they are young (SMS397, SMS409), and when older, have large prominent noses (Chung 1 2012 and SMS376). Strabismus and periorbital fullness were frequently noted (SMS409, SMS376, Chung 2 2012 and SMS397) ( Table 1, Figures 2 and 3) . Unspecified dental abnormalities, such as widely spaced teeth, were also commonly noted (Table 1) . Mild hand and foot abnormalities were seen in almost all subjects (Table 1, Figure 2) . Notably, large, broad first toes were mentioned in all of the patients evaluated, and fifth finger clinodactyly was a common finding (Table 1, Figure 3 ). Two patients (3424_3b 3 and MGH2) had relative macrocephaly (MGH2 with OFC 90th centile We compared the core phenotypes observed in three distinct categories of MBD5 alteration, (1) MBD5 point mutations, (2) MBD5 deletions and (3) MBD5 duplications ( Table 2 ). All mutations, deletions and duplications share developmental delay, motor delay, language impairment, behavioral problems and autistic-like symptoms. Interestingly, seizures, which were seen in individuals with MBD5 mutations, MBD5-specific deletions and 2q23.1 deletions, were rarely observed in MBD5 duplications. In addition to the features noted above, the 2q23.1 deletion and duplication cases, some of which are very large, spanning from 0.068 Mb to 53.7 Mb in size, have infantile hypotonia, arched eyebrows and nasal anomalies, with minimal clinical differences between the two groups. These data suggest that genes flanking MBD5 may contribute to these additional features ( Figure 1 , Table 2 ). Overall, these findings further support an effect of MBD5 gene dosage as the likely cause for the core phenotypes observed in 2q23.1 deletion and duplication syndromes.
Gene dosage of MBD5
We previously established haploinsufficiency of MBD5 in promoter, 5 0 -noncoding exon, or coding exon deletions in 2q23.1 deletion subjects (Figure 4 ). 1 Here, we assessed the level of MBD5 expression in cells from 2q23.1 duplication subjects and compared these levels to MBD5 expression in cells from 2q23.1 deletion subjects (Figure 4) . Data showed that MBD5 mRNA expression levels were significantly increased (1.52-to 1.83-fold) across all 2q23.1 duplications studied when compared with normal controls (Figure 4) . The MBD5 mRNA expression levels for the 2q23.1 deletions were 0.22-to 0.59-fold compared with normal controls (Figure 4 ). 1 The expression changes observed indicate that MBD5 is a dosage-sensitive gene and that improper dosage of this gene could be the cause of the core phenotype that distinguishes 2q23.1 deletion and duplication subjects.
DISCUSSION
We report 23 new patients with a 2q23.1 duplication, which we believe represent a reciprocal duplication syndrome complementary to the 2q23.1 microdeletion syndrome. The microduplication sizes vary for all cases and range from 68 kb to 453 Mb. Each duplication has distinct proximal and distal breakpoints, suggesting that the variants, similar to 2q23.1 microdeletions, are not mediated by lowcopy repeats. As these deletions and duplications are likely not mediated by NAHR, they are likely caused by the genomic rearrangement mechanism known as fork-stalling and template-switching/ microhomology-mediated break-induced replication. 10 This mechanism also has been reported in microduplication syndromes, including Potocki-Lupski syndrome and Charcot-Marie-Tooth disease type 1A and hereditary neuropathy with liability to pressure palsies. 10 Thus, it is possible that the duplications observed in the patients with this syndrome are mediated by this mechanism. Additional studies are in progress to understand the breakpoint sequences in several 2q23.1 deletion and duplication patients, which will help us understand the etiology of deletions and duplications in 2q23.1 syndromes.
All duplications encompass a region that includes either all or a portion of MBD5, an important protein in methylation patterning and epigenetic regulation. 1, 11, 12 The resulting phenotype includes ID, language impairments, infantile hypotonia and gross motor delay, behavioral problems, autistic features, dysmorphic facial features (pinnae anomalies, arched eyebrows, prominent nose, small chin, thin upper lip) and minor digital anomalies (fifth finger clinodactyly and large broad first toe). In-depth clinical features for all 23 individuals were difficult to obtain; thus, having more individuals with ascertainment of in-depth clinical features of this disorder will contribute to our knowledge regarding the spectrum of phenotype present in individuals with MBD5-associated disorders. Both partial and whole-gene duplication of MBD5 resulted in altered gene dosage, thus illustrating that MBD5 is overexpressed in cells from 2q23.1 microduplication patients. We are aware that gene expression in LCLs in a neurodevelopmental disorder may have its limitations and may not be the best tissue for molecular and functional studies of a neurodevelopmental disorder. Analysis of MBD5 in other model systems, such as mouse and induced pluripotent stem cells, will provide insight into cellular requirement for normal MBD5 dosage. Overexpression associated with a partial gene duplication is important to note because diagnostic laboratories might conclude that partial gene duplications are not pathogenic. However, the cases presented here illustrate that duplication of non-coding exons may be sufficient for overexpression and further illustrate the complexity of the effects of genomic alteration on transcription. Additional studies will be required to fully understand the transcripts that are produced in these variants. The phenotype associated with a deletion, mutation or duplication of MBD5 combined with the gene expression changes observed suggests that MBD5 is a dosage-sensitive gene critical for normal development. Several genomic disorders are caused by CNVs involving one or more dosage-sensitive genes (Table 3) . Thus, MBD5 and chromosome 2q23.1 can be added to an expanding list of dosage-sensitive genomic regions that result in reciprocal deletion and duplication neurodevelopmental syndromes (Table 3) . 13, 14 Some dosage-sensitive genes when deleted or duplicated result in similar phenotypes, such as MECP2. 13, 15 For other disorders, deletions and duplications involving the same dosagesensitive genes result in significantly different clinical presentations, such as seen in Williams syndrome and chromosome 7q11.23 duplication syndrome. 13, 16 From the current study, it appears that MBD5 falls into the former category of dosage-sensitive genes, but additional cases will need to be studied to determine if there are features which have not been identified or are underappreciated. The phenotypes observed in the microdeletion and microduplication syndrome are similar, with the 2q23.1 microduplication syndrome having a somewhat milder phenotype. The absence of seizures in the duplication cohort is a notable difference. Previous studies have suggested that genomic duplications can present with a subtler phenotype. As we have shown in this study, there is significant potential for duplication carriers to go undetected. 17 Furthermore, these carriers may transmit their duplication to their offspring, who may exhibit a more severe phenotype. 18 We have three duplication cases in our cohort that exhibit maternal inheritance who all exhibit severe phenotypes in comparison to their mothers. Analysis of additional patient and parent samples will elucidate if there is a maternal inheritance bias or possible imprinting effect associated with this 2q23.1 region and the potential familial variable expressivity of the duplication syndrome. We previously implicated deletions of MBD5 as clearly deleterious genomic alterations 1 and now provide data to support that duplications of MBD5 also confer risk. Given the rare parental transmission of alterations of MBD5 (whether deletion, mutation or duplication), these are not fully penetrant alterations. They were discovered by the assessment of non-recurrent CNVs and translocations across testing sites to identify the minimal region of overlap. By definition, these non-recurrent events are not polymorphisms. Moreover, the effect size reported previously 1 and in this study suggests disruption of the locus is rare in individuals without neurodevelopmental abnormalities. There is no evidence from any studies to date to suggest benign, common polymorphisms disrupt the exonic regions of MBD5; however, the data are insufficient to empirically determine the frequency of small recurrent events confined to intronic regions with current technical resolution; thus, the effect of intronic events within MBD5 is not known at this time and requires additional study.
Further, we illustrate overlap between the features of 2q23.1 duplication and other syndromes such as Williams syndrome, fragile X syndrome, Rubinstein-Taybi syndrome, Smith-Magenis syndrome, Angelman syndrome and Prader-Willi syndrome. The cheerful demeanor and ease with strangers that is seen in Williams syndrome is also seen in some 2q23.1 duplication patients. 19 Behavioral characteristics such as stereotypic movements and self-injurious behavior that are seen in 6/9 of the duplication subjects are also seen in fragile X syndrome and Smith-Magenis syndrome. 20, 21 The likeable and happy disposition of 2q23.1 duplication subjects is also present in the Angelman syndrome phenotype. 22 The broad first toes, which are prevalent in the duplication subjects are also found in the RubinsteinTaybi phenotype; however, broad thumbs were not observed. 23 These similarities between phenotypes suggest that the genes causative for these syndromes are possibly involved in overlapping molecular networks that, when altered, contribute to the observed phenotypes.
Overall, these findings suggest that precise gene dosage of MBD5 is clearly required for normal development of speech/language and normal cognitive functions. Furthermore, these findings support a role for MBD5 in neuronal development by mediating central nuclear functions important for regulation of gene dosage and expression. Finally, based on the similarity of MBD5 disorders to other well-known syndromes, testing for MBD5 dosage changes and/or mutation should be considered after molecular diagnosis for certain neurodevelopmental disorders proves futile.
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